コンテンツへスキップ
Merck
  • Human immunodeficiency virus-specific gamma interferon enzyme-linked immunospot assay responses targeting specific regions of the proteome during primary subtype C infection are poor predictors of the course of viremia and set point.

Human immunodeficiency virus-specific gamma interferon enzyme-linked immunospot assay responses targeting specific regions of the proteome during primary subtype C infection are poor predictors of the course of viremia and set point.

Journal of virology (2008-10-24)
Clive M Gray, Mandla Mlotshwa, Catherine Riou, Tiyani Mathebula, Debra de Assis Rosa, Tumelo Mashishi, Cathal Seoighe, Nobubelo Ngandu, Francois van Loggerenberg, Lynn Morris, Koleka Mlisana, Carolyn Williamson, Salim Abdool Karim
要旨

It is unknown whether patterns of human immunodeficiency virus (HIV)-specific T-cell responses during acute infection may influence the viral set point and the course of disease. We wished to establish whether the magnitude and breadth of HIV type 1 (HIV-1)-specific T-cell responses at 3 months postinfection were correlated with the viral-load set point at 12 months and hypothesized that the magnitude and breadth of HIV-specific T-cell responses during primary infection would predict the set point. Gamma interferon (IFN-gamma) enzyme-linked immunospot (ELISPOT) assay responses across the complete proteome were measured in 47 subtype C HIV-1-infected participants at a median of 12 weeks postinfection. When corrected for amino acid length and individuals responding to each region, the order of recognition was as follows: Nef > Gag > Pol > Rev > Vpr > Env > Vpu > Vif > Tat. Nef responses were significantly (P < 0.05) dominant, targeted six epitopic regions, and were unrelated to the course of viremia. There was no significant difference in the magnitude and breadth of responses for each protein region with disease progression, although there was a trend of increased breadth (mean, four to seven pools) in rapid progressors. Correlation of the magnitude and breadth of IFN-gamma responses with the viral set point at 12 months revealed almost zero association for each protein region. Taken together, these data demonstrate that the magnitude and breadth of IFN-gamma ELISPOT assay responses at 3 months postinfection are unrelated to the course of disease in the first year of infection and are not associated with, and have low predictive power for, the viral set point at 12 months.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
ジメチルスルホキシド, Hybri-Max, sterile-filtered, BioReagent, suitable for hybridoma, ≥99.7%
Sigma-Aldrich
ジメチルスルホキシド, ACS reagent, ≥99.9%
Sigma-Aldrich
ジメチルスルホキシド, for molecular biology
Sigma-Aldrich
ジメチルスルホキシド, suitable for HPLC, ≥99.7%
Sigma-Aldrich
ジメチルスルホキシド, sterile-filtered, BioPerformance Certified, meets EP, USP testing specifications, suitable for hybridoma
Sigma-Aldrich
ジメチルスルホキシド, ReagentPlus®, ≥99.5%
Sigma-Aldrich
ジメチルスルホキシド, ≥99.5% (GC), suitable for plant cell culture
Sigma-Aldrich
ジメチルスルホキシド, anhydrous, ≥99.9%
Sigma-Aldrich
ジメチルスルホキシド, puriss. p.a., ACS reagent, ≥99.9% (GC)
Sigma-Aldrich
ジメチルスルホキシド, BioUltra, for molecular biology, ≥99.5% (GC)
Sigma-Aldrich
ジメチルスルホキシド, puriss. p.a., dried, ≤0.02% water
Sigma-Aldrich
ジメチルスルホキシド, PCR Reagent
Sigma-Aldrich
ジメチルスルホキシド, meets EP testing specifications, meets USP testing specifications
Supelco
ジメチルスルホキシド, analytical standard
Sigma-Aldrich
ジメチルスルホキシド, ≥99.5%
Sigma-Aldrich
ジメチルスルホキシド, suitable for HPLC
Sigma-Aldrich
ジメチルスルホキシド, JIS special grade, ≥99.0%
Sigma-Aldrich
ジメチルスルホキシド, SAJ first grade, ≥99.0%
Sigma-Aldrich
ジメチルスルホキシド, ≥99.0%, suitable for absorption spectrum analysis